Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
368
datasets available to search
ShareScore release 0.9.0
Dataset results
368 results for “HIV testing”
HOSENG trial – HOme-based oral SElf-testiNG for absent and refusing individuals during a door-to-door HIV testing campaign: a cluster randomised clinical trial in rural Lesotho
<p>These are pseudo-anonymised data from the HOSENG randomized trial: " HOSENG trial – HOme-based oral SElf-testiNG for absent and refusing individuals during a door-to-door HIV testing campaign: a cluster randomised clinical trial in rural Lesotho". The data dictionary explains the data available in the dataset. Between July 2018 and December 2018, 10516 eligible individuals from 106 consenting villages were enrolled from two districts of Lesotho, and followed up for a maximum of 120 days. Main manuscript reference, DOI: <a href="https://doi.org/10.1016/s2352-3018(20)30233-2">10.1016/S2352-3018(20)30233-2. </a>The protocol was published, DOI:10.1186/s13063-019-3469-2.</p>
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
ClinicalTrials.gov study NCT04124536. IPD Sharing: YES. Countries: 1. Publications: 1.
CHALO! 2.0: A Mobile Technology Based Intervention to Accelerate HIV Testing and Linkage to Preventive Treatment.
ClinicalTrials.gov study NCT04814654. IPD Sharing: YES. Countries: 1. Publications: 1.
Deep-sequence phylogenetics to quantify patterns of HIV transmission in the context of a universal testing and treatment trial – BCPP/ Ya Tsie trial
<p><strong>Background:</strong> Mathematical models predict that community-wide access to HIV testing-and-treatment can rapidly and substantially reduce new HIV infections. Yet several large universal test-and-treat HIV prevention trials in high-prevalence epidemics demonstrated variable reduction in population-level incidence.</p> <p><strong>Methods:</strong> To elucidate patterns of HIV spread in universal test-and-treat trials we quantified the contribution of geographic-location, gender, age and randomized-HIV-intervention to HIV transmissions in the 30-community Ya Tsie trial in Botswana (estimated trial population: 175,664).</p> <p><strong>Results:</strong> Deep-sequence phylogenetic analysis revealed that most inferred HIV transmissions within the trial occurred within the same or between neighboring communities, and between similarly-aged partners. Transmissions into intervention communities from control communities were more common than the reverse post-baseline (30% [12.2 – 56.7] versus 3% [0.1 – 27.3]) than at baseline (7% [1.5 – 25.3] versus 5% [0.9 – 22.9]) compatible with a benefit from treatment-as-prevention.</p> <p><strong>Conclusion:</strong> Our findings suggest that population mobility patterns are fundamental to HIV transmission dynamics and to the impact of HIV control strategies.</p> <p><strong>Funding:</strong> This study was supported by the National Institute of General Medical Sciences (U54GM088558); the Fogarty International Center (FIC) of the U.S. National Institutes of Health (D43 TW009610); and the President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention (CDC) (Cooperative agreements U01 GH000447 and U2G GH001911).</p>
Risky sexual behaviours and utilization of HIV testing services among the adolescent girls and young women aged between 15-24 years in Kibra Sub County, Nairobi County, Kenya
<p><strong>Introduction: </strong>HIV remains a significant global health challenge, disproportionately affecting adolescent girls and young women (AGYW). HIV testing is crucial in controlling the infection and reducing its prevalence. Understanding risky sexual behaviors among AGYW is pivotal in aligning prevention interventions. Despite global prevention efforts, testing gaps persist among AGYW, linked to risky sexual behavior (RSB). This study explores the association between these behaviors and HIV testing utilization among AGYW (aged 15-24) in Kibra Sub County, Nairobi.</p> <p><strong>Methods: </strong>A cross-sectional study sampled 379 AGYW from three wards in Kibra Sub County in Nairobi County. To be an eligible participant, one must have been a resident for at least one year before the time of the study and aged between 15-24 years, employing standardized structured interviewer-administered questionnaires and statistical analyses. Results were analyzed using Chi-square tests and logistic regression. Data was collected between June to July 2023.</p> <p><strong>Results: </strong>Overall, HIV testing prevalence was 60.7% (n=230). Those aged 20-24 were 71.3% (n=164), with secondary education were 63.5% (n=146) and married 28.7% (66) were more likely to undergo testing. Participants engaging in risky behaviors such as lack of condom use (3.96 times more likely), experiencing gender-based violence (4.65 times more likely), or contracting STIs (2.85 times more likely) had higher odds of seeking HIV testing services.</p> <p><strong>Conclusion: </strong>This study establishes a clear link between risky sexual behaviors and HIV testing among AGYW, with a 60.7% testing prevalence; however, gaps still exist. Efforts to enhance testing rates are vital. Interventions should align with acceptable methods, focusing on this high-risk group to ensure effective HIV care and prevention.</p>
Dataset: Impact of HIV knowledge and stigma on the uptake of HIV testing - results from a community-based participatory research survey among migrants from sub-Saharan Africa in Germany
<p>Dataset for: Kuehne A, Koschollek C, Santos-Hövener C, Thorlie A, Müllerschön J, Tshibadi CM, Mayamba P, Batemona-Abeke H, Amoah S, Greiner VW, Bursi TD, Bremer V: Impact of HIV knowledge and stigma on the uptake of HIV testing - results from a community-based participatory research survey among migrants from sub-Saharan Africa in Germany.</p> <p>This dataset has been described in a PLoS One paper and contains all data necessary to replicate the results presented within this paper (10.1371/journal.pone.0194244). Please cite both the paper as well as the DOI of this dataset if you make use of the data.</p>
Isoniazid Preventive Therapy (IPT) uptake and Tuberculin Skin Test (TST) uptake among adults receiving primary HIV care in South Africa .
<p>We aimed to evaluate Isoniazid Preventive Therapy (IPT) and tuberculin skin testing (TST) uptake under primary care clinic conditions, and determine health care worker (HCW) fidelity to the 2014 South African IPT guidelines. Following training on IPT guidelines and tuberculin skin testing (TST), 3 primary care clinics identified their IPT implementation strategy in a participatory manner. Using routine register data, TST uptake was determined 3 months before and 5 months after the intervention. Records were reviewed to identify IPT/TST uptake and factors associated with IPT initiation among adults living with HIV.</p>
Data from: Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): a randomized trial and cost-effectiveness analysis
<p>Suboptimal tuberculosis (TB) diagnostics and HIV contribute to the high global burden of TB. We investigated costs and yield from systematic HIV-TB screening, including computer-aided digital chest X-ray (DCXR-CAD). Suboptimal tuberculosis (TB) diagnostics and HIV contribute to the high global burden of TB. We investigated costs and yield from systematic HIV-TB screening, including computer-aided digital chest X-ray (DCXR-CAD).</p> <p>In this open, three-arm randomised trial, adults (≥18 years) with cough attending acute primary services in Malawi were randomised (1:1:1) to standard-of-care (SOC); oral HIV testing (HIV screening) and linkage to care; or HIV testing and linkage to care plus DCXR-CAD with sputum Xpert for high CAD4TBv5 scores (HIV-TB screening). Participants and study staff were not blinded to intervention allocation, but investigator blinding was maintained until final analysis. The primary outcome was time to TB treatment. Secondary outcomes included proportion with same-day TB treatment; prevalence of undiagnosed/untreated bacteriologically-confirmed TB on day 56; and undiagnosed/untreated HIV. Analysis was done on an intention to treat basis. Cost-effectiveness analysis used a health-provider perspective. Between 15/11/2018-27/11/2019, 8236 were screened for eligibility, with 473, 492, and 497 randomly allocated to SOC, HIV, and HIV-TB screening arms; 53 (11%), 52 (9%), and 47 (9%) were lost to follow-up, respectively. At 56 days, TB treatment had been started in 5 (1.1%) SOC, 8 (1.6%) HIV-screening, and 15 (3.0%) HIV-TB screening participants. Median (IQR) time to TB treatment was 11 (6.5-38), 6 (1-22) and 1 (0-3) days (hazard ratio for HIV-TB vs. SOC: 2.86, 1.04-7.87), with same-day treatment of 0/5 (0%) SOC, 1/8 (12.5%) HIV, and 6/15 (40.0%) HIV-TB screening arm TB patients (p=0.03). At day 56, 2 SOC (0.5%), 4 HIV (1.0%), and 2 HIV-TB (0.5%) participants had undiagnosed microbiologically-confirmed TB. HIV screening reduced the proportion with undiagnosed or untreated HIV from 10 (2.7%) in the SOC arm to 2 (0.5%) in the HIV-screening arm (risk ratio [RR]: 0.18, 0.04-0.83), and 1 (0.2%) in the HIV-TB screening arm (RR: 0.09, 0.01-0.71). Incremental costs were US$3.58 and US$19.92 per participant screened for HIV and HIV-TB; the probability of cost-effectiveness at a US$1200/quality-adjusted life-year (QALY) threshold were 83.9% and 0%. Main limitations were the lower than anticipated prevalence of tuberculosis and short participant follow-up period; cost and quality of life benefits of this screening approach may accrue over a longer time horizon.</p> <p>DCXR-CAD with universal HIV screening significantly increased the timeliness and completeness of HIV and TB diagnosis. If implemented at scale this has potential to rapidly and efficiently improve TB and HIV diagnosis and treatment.</p>
Country uptake of WHO recommendations on differentiated HIV testing services approaches: A global policy review
<p><strong>Objectives </strong></p> <p>In 2015 and 2016, the World Health Organization (WHO) issued guidelines on HIV testing services (HTS) highlighting recommendations for a strategic mix of differentiated HTS approaches. The Policy review examines the uptake of differentiated HIV Testing service (HTS) approaches recommendations.</p> <p><strong>Methods </strong></p> <p>Data were extracted from all available national policies published between January 2015 and June 2019 and stored in WHO's national policy repository. WHO recommended as HTS approaches facility-based testing, community-based testing, HIV self-testing and provider-assisted referral (or assisted partner notification); in terms of testing components: pre-test information, lay provider testing and rapid testing. Descriptive analyses were conducted to examine availability of policies and adherence to WHO-differentiated HTS recommendations.</p> <p><strong>Results</strong></p> <p>Of 194 countries worldwide, 65 published policies were identified in the review period. 24 were from the African region (51% of African countries, 24/47), six from the Eastern Mediterranean region (29%, 6/21), 21 from the European region (40%, 21/53), five from the American region (14%, 5/35), four from the South East Asia region (36%, 4/11) and five from the Western Pacific Region (19%, 5/27). Only five countries were compliant with recommendations and 63 included at least one. 85% (n=55) included facility-based testing for pregnant women, 75% (n=49) facility-based testing for key populations, 74% (n=48) community-based testing for key populations, 38% (n=25) HIV self-testing, 25% (n=16) provider-assisted referral, 69% (n=45) rapid testing, 57% (n=37) post-test counselling, 45% (n=29) lay provider testing and 29% (n=19) pre-test information. The highest uptake of WHO recommendations was seen in countries from the African and Eastern Mediterranean region.</p> <p><strong>Conclusions</strong></p> <p>There was substantial variability in the uptake of WHO HTS recommendations, ranging from 25% to 85%. Uptake was above 50% for facility-based testing for pregnant women and key populations, community-based testing, rapid diagnostic testing and post-test counselling; uptake was between 25% and 45% for all the other recommendations.</p>
The HIV Testing Using Enhanced Screening Techniques in Emergency Departments Trial
ClinicalTrials.gov study NCT01781949. IPD Sharing: YES. Countries: 1. Publications: 2.
Using Social Media to Deliver HIV Self-Testing Kits and Link to Online PrEP Services
ClinicalTrials.gov study NCT04155502. IPD Sharing: YES. Countries: 1. Publications: 2.
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
ClinicalTrials.gov study NCT02595866. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs
ClinicalTrials.gov study NCT03282890. IPD Sharing: NO. Countries: 1. Publications: 11.
Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests
ClinicalTrials.gov study NCT01790633. IPD Sharing: YES. Countries: 1. Publications: 2.
Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)
ClinicalTrials.gov study NCT01161446. IPD Sharing: Not stated. Countries: 1. Publications: 1.
HIV Oral Testing Infographic Experiment
ClinicalTrials.gov study NCT04061915. IPD Sharing: NO. Countries: 1. Publications: 5.
HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST LAIs) in Nigeria
ClinicalTrials.gov study NCT07000513. IPD Sharing: NO. Countries: 1. Publications: 2.
Community Based Screening for HIV Self Testing in FSW in 23 Priority Districts in Indonesia
ClinicalTrials.gov study NCT04578145. IPD Sharing: NO. Countries: 1. Publications: 20.
Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners
ClinicalTrials.gov study NCT03271307. IPD Sharing: NO. Countries: 1. Publications: 4.
HIV Self Testing of Male Partners of Women in PMTCT
ClinicalTrials.gov study NCT03484533. IPD Sharing: NO. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.